anti-Asprosin (human) mAb (Birdy-2)

AdipoGen Life Sciences
Product Code: AG-20B-0074
Product Group: Primary Antibodies
CodeSizePrice
AG-20B-0074-C100100 ug£315.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Antibody Isotype: Mouse IgG2a
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Human
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Western Blot (WB)
Shipping:
Blue Ice
Storage:
-20°C

Further Information

Alternate Names/Synonyms:
Fibrillin-1 C-terminal Cleavage Product; FBN1 C Terminal Cleavage Product
Concentration:
1mg/ml
EClass:
32160000
Form (Short):
liquid
Formulation:
Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.
Handling Advice:
After opening, prepare aliquots and store at -20°C.Avoid freeze/thaw cycles.
Immunogen:
Recombinant human asprosin.
Long Description:
Monoclonal Antibody. Recognizes human asprosin and human fibrillin-1 (by homology). Isotype: Mouse IgG2a. Clone: Birdy-2. Application: ELISA, WB. Liquid. In PBS containing 10% glycerol and 0.02% sodium azide. Asprosin is a new fasting-induced protein hormone that targets the liver to increase plasma glucose levels. Asprosin is the C-terminal cleavage product of the protein fibrillin-1. Asprosin is secreted from white adipose tissue and increases hepatic glucose production by using cAMP as a second messenger, leading to activation of protein kinase A in the liver. Reduction of asprosin levels protect against metabolic syndrome-associated hyperinsulinism.
Package Type:
Plastic Vial
Product Description:
Asprosin is a new fasting-induced protein hormone that targets the liver to increase plasma glucose levels. Asprosin is the C-terminal cleavage product of the protein Fibrillin-1. Asprosin is secreted from white adipose tissue and increases hepatic glucose production by using cAMP as a second messenger, leading to activation of protein Kinase A. Reduction of Asprosin levels protects against metabolic syndrome-associated hyperinsulinism. Asprosin may act as a circulating hunger signal. Indeed, peripherally injected recombinant asprosin can cross the blood-brain barrier and intracerebroventricular (i.c.v.) injection of recombinant asprosin stimulated appetite in wild-type mice, indicating a central mechanism of action. Loss of Asprosin in mice and human leads to decreased fat mass and body weight, and hypophagia. Mice are also completely protected from the development of diet-induced obesity. Asprosin works by stimulating the orexigenic AgRP+ (Agouti related neuropeptide) neurons via a cAMP-dependent pathway and by inhibiting the anorexigenic neurons POMC+ (pro-opiomelanocortin) neurons in a GABA-dependent manner. Mutation in Asprosin in human leads to the pattern of metabolic dysregulation, including partial lipodystrophy, accompanied by reduced plasma insulin. Due to its key role in food regulation, Asprosin function could serve as a potentially unique therapeutic target against obesity, diabetes or metabolic diseases.
Purity:
>95% (SDS-PAGE)
Source / Host:
Purified from concentrated hybridoma tissue culture supernatant.
Specificity:
Recognizes human asprosin and human fibrillin-1 (by homology).
Transportation:
Non-hazardous
UNSPSC Category:
Primary Antibodies
UNSPSC Number:
12352203
Use & Stability:
Stable for at least 1 year after receipt when stored at -20°C.

References

Continuous elevation of plasma asprosin in pregnant women complicated with gestational diabetes mellitus: A nested case-control study: L. Zhong, et al.; Placenta 93, 17 (2020)